Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets
Abstract
There exist a large number of cohort studies that have been used to identify genetic and biological risk factors for developing Alzheimer's disease (AD). However, there is a disagreement between studies as to how strongly these risk factors affect the rate of progression through diagnostic groups toward AD. We have calculated the probability of transitioning through diagnostic groups in six studies and considered how uncertainty around the strength of the effect of these risk factors affects estimates of the distribution of individuals in each diagnostic group in an AD clinical trial simulator. In this work, we identify the optimal choice of widely collected variables for comparing data sets and calculating probabilities of progression toward AD. We use the estimated transition probabilities to inform stochastic simulations of AD progression that are based on a Markov model and compare predicted incidence rates to those in a community‐based study, the Cardiovascular Health Study.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1016/j.trci.2019.04.005
Entities
People
- Add Neuro Med Consortium
- Christoforos Hadjichrysanthou
- David Ames
- Frank De Wolf
- Kevin Mcrae‐mckee
- Mei Mei Wong
- Oscar Lopez
- Predictors Of Cognitive Decline Among Normal Individuals (biocard) Study
- Roy M. Anderson
- Stephanie Evans
- The Alzheimer’s Disease Neuroimaging Initiative*
- The Australian Imaging Biomarkers And Lifestyle Flagship Study Of Ageing
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Boston University
- Bristol-Myers Squibb
- Chiron Corporation
- Dementia Collaborative Research Centres
- Eisai
- Eli Lilly and Company
- European Commission
- GE HealthCare
- Hoffmann-La Roche
- Imperial College London
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Ageing Research Institute
- National Health and Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Science and Industry Endowment Fund
- Swedish Brain Power
- Takeda Pharmaceutical Company
- University of Melbourne
- University of Pittsburgh